A monoclonal antibody, selected for reactivity with the Epstein-
Introduction
Several lines of evidence have indirectly implicated Epstein-Barr virus (EBV)' in the etiology of rheumatoid arthritis (RA) (1). 1 . Abbreviations used in this paper: CMV, cytomegalovirus; DAB, 3'3' diaminobenzidine; EBNA-1, nuclear antigen with 70,000-80,000 mol wt; EBV, Epstein-Barr virus; FCS, fetal calf serum; HSV-I and HSV-2, herpes simplex virus types 1 and 2, respectively; HTLV-1, human Tleukemia virus type 1; IR-3, internal repeat region 3; MAb, monoclonal EBV is a potent polyclonal B cell activator capable of inducing rheumatoid factor (anti-human IgG) synthesis (2) . RA patients have higher titers ofanti-EBV antibodies than age-matched controls (3) (4) (5) , and peripheral blood lymphocytes from these patients have an increased proportion of circulating B cells infected by EBV (2, 6) , which is perhaps due to an abnormal response of their T cells to EBV infection (7, 8) . Nevertheless, direct evidence for the involvement of EBV in the pathogenesis of RA is still lacking. A recent study by Alspaugh et al. (9) failed to find increased levels of EBV DNA within RA synovial membranes. However, low amounts of viral DNA would not be detected using these methods of hybridization. Therefore, we used monoclonal antibodies (MAbs) and immunohistologic techniques to determine whether RA synovial tissues contained cells that were infected with EBV or that contained antigens crossreactive with EBV-encoded antigens.
Transformation of B lymphocytes by EBV leads to expression of a nuclear antigen with a molecular weight of 70,000-85,000 termed EBNA-1. The function of this DNA binding protein remains unknown, but recent studies have suggested that it may play a role in regulating viral and perhaps cellular DNA synthesis (10) . An unusual feature of EBNA-1 is the presence of a long repetitive sequence of glycine and alanine that may extend to over 200 amino acids (1 1) . This portion ofthe EBNA-l molecules is encoded by the internal repeat region 3 (IR-3) of the EBV genome (12) . Recently, Luka et al. (13) used EBNA-1 as an immunogen to produce an MAb (MAb P135) that reacted with an antigenic epitope encoded by the IR-3 region of EBV. Specifically, this antibody was able to immunoprecipitate the fusion protein of the glycine-alanine domain of EBNA-1 and f3-galactosidase (13) . They also found that this MAb reacted with a 62,000-mol-wt protein in lymphoblastoid cell lines lacking the EBV genome (13) . The structural basis for this cross-reactivity probably resides in the presence of IR-3-like genes in normal human genomic DNA (12) . The "cellular" 62,000-mol-wt protein differed from the EBNA-l antigen in its peptide map and in its predominantly cytoplasmic location (13) . Of importance, sera from patients with infectious mononucleosis produced antibodies against the 62,000-mol-wt protein in parallel with antibodies against the EBNA-I antigen, indicating the occurrence of a cross-reactive antigen in vivo. The 
Methods
Patient population. Rheumatoid synovial tissue was obtained from 12 patients with definite or classic seropositive RA at the time of synovectomy or total joint replacement. Synovial membranes were obtained from 11 patients with osteoarthritis, 4 patients with non-RA synovitis (systemic lupus erythematosus [SLE] , pigmentary villonodular synovitis, psoriasitic arthritis, and Reiter's syndrome) at the time of total joint replacement and from two immunologically normal individuals undergoing arthroscopic knee surgery for cartilage repair. The clinical and histologic features of these RA and non-RA synovial tissues has recently been presented (14). Titers of rheumatoid factor (anti-human IgG) and anti EBNA-1 antibodies were detected as previously described (5, 14, 15) .
MAbs. MAbs against EBV-associated antigens that were used in this study are summarized in Table I . MAb P135 was prepared by immunizing murine splenocytes with purified EBNA-I (13) and selected for reactivity with this antigen. As described above, it subsequently became apparent that MAb P135 was not specific for EBNA-1, since EBV genome-negative lymphoblastoid cell lines also expressed a cross-reacting 62,000-mol-wt antigen (13 (Table I) . Antibody SC2 detects a nonpolymorphic determinant on histocompatibility antigen HLA-DR (15). Antibody Leu-CR3 (Becton-Dickenson & Co., Oxnard, CA) reacts with the complement receptor CR3, which binds the complement fragment iC3b. Complement CR3 receptors have previously been demonstrated to be present on RA synovial lining cells, monocytes, and other cells of hematopoietic origin (14, (22) (23) (24) . Control murine hybridoma antibodies lacking anti-human activity included MOPC-21 (IgG 1-kappa) Rl-l (IgG 2-kappa), and F40 (IgM-kappa).
Specific MAbs were used as a tissue culture supernatant (5 ;g/ml) or as a dilution of immunoglobulin purified from ascites (10-25 Ag/ml).
Antibodies produced against synthetic peptides denrvedfrom the DNA sequence ofEBNA-1. To further characterize the antigen(s) in RA synovium, we used rabbit antibodies directed against synthetic peptides (IR3-VI-0 and IR3-VI-2) (25) and immunoblotting methods. These synthetic peptides are from adjacent regions of the glycine-alanine-rich region of EBNA-I encoded by the IR-3 region of the EBV genome. Rabbits were immunized subcutaneously, with these synthetic peptides covalently linked to keyhole limpet-hemocyanin (KLH) using complete Freund's adjuvant. Preparation of tissue extracts and immunoblotting. Fresh surgical biopsies of synovial membrane tissue from RA patients (four patients), osteoarthritis synovial membranes (three patients), or normal tonsillar lymph node (three patients) were cut in I X 1-cm blocks, frozen in liquid nitrogen, and fragmented into small pieces with a hammer. The resulting powder was solubilized with 0.5% NP40 (Shell Oil Co., Houston, TX), 0.4 M NaCl, 20 mM Tris/HCl (pH 7.4) containing 1 mM phenylmethylsulfonyl fluoride. The extracts were then centrifuged at 40,000 g for 45 min. The protein content of the supernatant was determined by the Lowry method and amido black staining of dot blots followed by laser densitometry as previously described (26) . Samples containing 50 ul of tissue extract (containing 1-10 mg/ml protein content) were electrophoresed under reducing conditions with 0.1% sodium dodecyl sulfate (SDS) on 8% polyacrylamide gels and the gels were electrophoretically transferred to nitrocellulose paper (26) . Nonspecific binding to the nitrocellulose paper was then blocked by incubation for 15 min in blotto, a powdered milk-based reagent (27) . MAb P135 or control murine myeloma protein was reacted at room temperature for I h, and followed by rabbit anti-mouse Ig at pretitered dilutions in blotto. Presence ofMAb P135 reactive material was assessed by reacting the paper strips with peroxidase-conjugated goat anti-rabbit Ig (Tago) followed by 0.05% 4-chloro-I-naphthol (4CN (Table II) . No significant staining of a serial section of RA synovium was obtained with a control IgM myeloma protein (a lower power photomicrograph is shown in Fig. 1 B) . Also, the synovial sections were not reactive with other anti-EBV MAbs, including MAb 2L10. 1 (anti-gp200/ 350), MAb V3 (anti-p 160), or MAb R63 (anti-EA-R) (data not shown).
In agreement with prior studies by others (28) (29) (30) and by our laboratory (14), we found that the majority of synoviallining cells from RA biopsies expressed intense staining with antibodies directed against HLA-DR antigen (Fig. 1 D and Table  II ) and complement receptor CR3 (Fig. 1 F) Fig. 3 A) . The proportion ofosteoarthritis synovial-lining cells stained by MAb P135 in osteoarthritis patients ranged from 2 to 10% (mean, 4±35%) in 7 of 12 patients and <2% in 5 of 12 patients (Table  II) . Scattered cells were also stained with anti-HLA-DR antibody (Fig. 3 C) , but no staining was noted with control myeloma protein (Fig. 3 B) . In a synovial biopsy from a patient with psoriatic arthritis, synovial-lining cells reactive with MAb P135 were present (Fig. 3 D) . In synovial biopsies from patients with Reiter's syndrome, SLE, and villonodular synovitis, only rare reactive cells were stained (Table II) . These latter biopsies from non-RA patients exhibited staining with anti-HLA-DR and anti-CR3 antibodies (Table II) , indicating that some synovial-lining cells express these antigens without being stained by MAb P135. Normal tissues were examined for reactivity with MAb P135 included liver, spleen, lymph node, brain, and kidney. No significant staining of these tissues was obtained with MAb P135 (Table II) .
Lack ofreactivity ofsynovial membranes with MAbs to CMV, HSV, or HTLV-I-associated antigens. Frozen tissue sections from RA synovial membrane were examined for reactivity with MAbs directed against CMV, HSV-1, HSV-2, and HTLV-l ( Fig. 4 , lane A demonstrates that MAb P135 reacts with the purified EBNA-1 antigen that has a molecular weight of 75,000 (13), while a control monoclonal antibody was nonreactive (Fig. 4, lane B) . When cell extracts from RA synovial membrane (lanes C-F) were probed with MAb P135, a 62,000-molwt band was detected. In contrast, no reactivity was noted when a similar amount of cell extract from osteoarthritis synovial membrane (Fig. 4, lanes G and H) was used. However, when 10-fold more osteoarthritis membrane extract was used, a 62,000-mol-wt band could be seen (Fig. 5, lanes D and E) . The molecular weight of this band was similar to that obtained from RA synovium (Fig. 5, lane B) . In addition to the 62,000-mol-wt band, a slightly lower band with a molecular weight -60,000 was also present in the osteoarthritis extracts and in some of the RA extracts.
To assess the completeness of the extraction procedure, the (13), we suspected that the antigenic epitope on the RA synovial membrane protein might be contained within the glycine-alanine-rich amino acid sequences that are present in EBNA-1. Therefore, we used a rabbit antibody prepared against a synthetic peptide (IR3-VI-0, that corresponds to a sequence encoded by the IR-3 region) and immunoblotting to evaluate cell and tissue extracts. As in Fig. 7 (lane B) , extracts ofan EBV-transformed cell line (Wil-2) contain a band of77,000-mol-wt, similar to the previously reported molecular weight of EBNA-l in this cell line (31) . In addition, a band at 62,000 can be noted. In lane C (Fig. 7) , extracts from a different EBV-transformed cell line contained a 72,000-mol-wt band as well as a band at 62,000 mol wt. Studies ofextracts from additional EBVtransformed cell lines (i.e., Raji, Daudi, and P3HR-1) have demonstrated a higher molecular weight band, ranging from 65,000-80,000 mol wt (corresponding to the known molecular weight of EBNA-1 in each cell line) plus an additional 62,000-mol-wt band (unpublished observations). Extracts from an EBVnegative cell line (BJAB) (Fig. 7, lane A) and from RA synovial membranes (Fig. 7, lanes D-F) contained bands with a molecular weight of -62,000. In contrast, normal and osteoarthritis synovial membranes (Fig. 7, lanes G-J) did not contain sufficient 62,000-mol-wt antigen to be detected by this antibody. The abil- To further characterize the antigens in RA synovial membrane, we used an additional rabbit anti-synthetic peptide antibody prepared against an adjacent region ofthe glycine-alaninerich region of EBNA-1 (peptide WR3-VI-0). This antibody reacts with purified EBNA-1 (Fig. 8, lane B) and with a 75,000-molwt band from an extract of EBV-transformed cells (Fig. 8, lane  C) . Of importance, no band at 62,000 mol wt was noted in Fig.  8 , lane C. When this same cell extract was probed with MAb P135, both the 75,000 and 62,000-mol-wt antigens were present (Fig. 8, lane A) . When extracts of RA synovial membrane were examined (Fig. 8 (30) . Thus, the immune system might be triggered to recognize the cross-reactive 62,000-mol-wt protein when presented in the context of the HLA-DR4 histocompatibility antigen. Second, previous studies have shown that RA patients have a higher "load" of EBV-transformed lymphocytes in their circulation (6) , and such infected cells may provide an increased antigenic stimulus to the RA patients. As a result, increased reactivity against the 62,000-mol-wt protein may develop. Finally, the cross-reactive 62,000-mol-wt protein might not be sterically available in the intact synovial membrane. Thus, release of increased amounts ofthe 62,000-mol-wt protein by proliferating synovial cells in RA patients or the degradation of the 62,000-mol-wt protein by synovial enzymes may present the immune system with an immunogenic stimulus.
The sharing ofantigenic determinants between an infectious agent and a normal cellular protein has been termed "molecular mimicry." The pathogenetic potential of such shared antigenic epitopes has long been recognized in rheumatic fever (35, 36) and more recently in Chagas' disease (37), myasthenia gravis (38) , and celiac sprue (39) . Another possible example of molecular mimicry is the antigenic cross-reactivity of intermediate filaments of the vimentin-type and viral proteins from herpes simplex or measles virus (40) (41) (42) . Although the cytoplasmic staining ofsynovial lining cells in situ and in vitro was suggestive of reaction with intermediary filaments such as vimentin, several lines ofevidence argue against this possibility. First, the molecular weight of the protein reactive with MAb P135 (i.e., 62,000) is higher than the 52,000-mol-wt vimentin molecule (40) . Second, the "cellular" 62,000-mol-wt protein can be solubilized in the presence of only NP40 detergent, while intermediate filaments are insoluble under these conditions. Thus, we suspect that 62,000-mol-wt antigen is a soluble protein that may associate with cytoskeletal elements and perhaps may influence cellular proliferation (43, 44) . Also, it is possible that the previously reported presence of antibodies against intermediate filaments in RA sera (45) may in part be directed against the 62,000-mol-wt protein.
Silverman and Schumacher (46) found no increase in anti-EBNA antibodies in the sera of RA patients early in the course of their disease. These workers used an immunofluorescence detection method that may yield different results than our enzyme-linked immunosorbent assay methods. For example, RA patients had elevated antibody titers only against certain glycinealanine-containing peptides (5) . Antibody responses against particular antigenic regions of EBNA-I might not be detectable in immunofluorescence assays. Also, preferential responses against particular antigenic regions of EBNA-I may be responsible for increased anti-RANA (RA nuclear antigen) antibody titers in RA patients (47) , since the RANA epitope appears to reside on the EBNA-I molecule (31) . Further studies on antibody and T cell responses ofRA patients early in the course ofdisease will be required to determine the potential importance of crossreactive antigens in pathogenesis.
In summary, we have found a 62,000-mol-wt protein bearing an antigenic epitope cross-reactive with EBNA-l in RA synovial membrane. The precise role of this cross-reactive antigen in the pathogenesis of RA remains unknown. However, antibodies to the 62,000-mol-wt protein are induced in parallel with anti-EBNA antibodies in patients with infectious mononucleosis (13) . Therefore, cross-reactions between EBNA-l and the 62,000-molwt cellular protein can occur in vivo. Since RA patients have elevated levels of antibodies directed against synthetic peptides encoded by the IR-3 region of EBV (5) , immune responses directed against a 62,000-mol-wt cross-reactive antigen may play a role in the initiation or perpetuation of their synovitis.
